- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Celgene Corporation (Nasdaq: CELG) hit a new 52-week high Thursday as it is currently trading at $115.67, above its previous 52-week high of $115.44 with 799,975 shares traded as of 10:31 a.m. ET. Average volume has been 3.8 million shares over the past 30 days. Celgene has a market cap of $47.1 billion and is part of the health care sector and drugs industry. Shares are up 44.3% year to date as of the close of trading on Wednesday. Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. The company has a P/E ratio of 34.1, above the S&P 500 P/E ratio of 17.7.